Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has earned a consensus recommendation of “Buy” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.38.

CRVS has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Tuesday, January 14th. StockNews.com lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avity Investment Management Inc. lifted its position in Corvus Pharmaceuticals by 7.6% during the 4th quarter. Avity Investment Management Inc. now owns 29,680 shares of the company’s stock worth $159,000 after buying an additional 2,100 shares in the last quarter. Geode Capital Management LLC lifted its position in Corvus Pharmaceuticals by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock worth $3,034,000 after buying an additional 3,854 shares in the last quarter. Renaissance Technologies LLC lifted its position in Corvus Pharmaceuticals by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 390,688 shares of the company’s stock worth $2,090,000 after buying an additional 4,100 shares in the last quarter. Nwam LLC lifted its position in Corvus Pharmaceuticals by 54.2% during the 4th quarter. Nwam LLC now owns 15,500 shares of the company’s stock worth $83,000 after buying an additional 5,450 shares in the last quarter. Finally, Virtus ETF Advisers LLC bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth about $47,000. 46.64% of the stock is owned by institutional investors.

Corvus Pharmaceuticals Stock Down 4.0 %

Shares of CRVS stock opened at $3.93 on Friday. Corvus Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $10.00. The firm has a market capitalization of $252.21 million, a price-to-earnings ratio of -4.22 and a beta of 1.07. The firm has a fifty day moving average of $5.16 and a 200-day moving average of $6.06.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.